2024年5月23日 · Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at around $600 million.

2024年4月14日 · Shanghai's Municipal Government recently announced a series of measures designed to boost and enhance research and development in the city's science and tech hub. CGTN's Sean Callebs had a chance to visit a German high-tech electronics manufacturing operation in Shanghai – and explains what's at stake.

Cell and gene therapy (CGT) describes a broad category of medicinal products with potential applications to prevent and treat human disease in multiple therapeutic areas. These therapies leverage the use of modified nucleic acids, altered cells or tissue, or both.

2024年11月20日 · German company Merck Testing said that the updated scope allows the company to localize advanced technologies in Shanghai's Free Trade Zone, engage in cutting-edge biotechnology innovation and better cater to China's biomedical development needs.

2022年9月1日 · Guardant Health has extended a partnership with Merck KGaA, Darmstadt, Germany, to aid in expediting precision oncology therapeutics development. Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas.

2024年5月24日 · 5月22日， 德国默克宣布将以6亿美元收购Mirus Bio，提高基于病毒载体的基因治疗产品的生产能力。 该交易预计今年第三季度完成。 Mirus Bio公司成立于1995年，总部位于美国，致力于细胞转染试剂的研发，通过化学转染试剂，电穿孔产品和病毒生产和转导产品。 病毒载体的生产是细胞和基因治疗产品生产过程中一个重要环节，稳健的瞬时转染是保证高产量和可靠的病毒载体大规模商业化生产的关键。 转染是通过非病毒手段将任何核酸分子引入培养的真核细 …

专注于CGT的全球化CTDMO. 药明生基是药明康德旗下专注于细胞和基因疗法的CTDMO (Contract Testing, Development and Manufacturing Organization) ，致力于加速和变革细胞和基因疗法及其他高端疗法的研究、开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法 ...

2024年11月28日 · As China is intensifying efforts to deepen international collaboration and investment in its high-tech medical sectors, frontier areas such as cell and gene therapy (CGT) will witness more growth opportunities with foreign participation, said industry experts.

3 天之前 · Learn about the challenges and strategies for overcoming barriers to the global adoption of cell and gene therapies (CGT) in this informative article.

2024年11月25日 · German company Merck Testing said that the updated scope allows the company to localize advanced technologies in Shanghai's Free Trade Zone, engage in cutting-edge biotechnology innovation and better cater to China's biomedical development needs.